FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results Read more
FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults Read more
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma Read more
Almirall and etherna enter into a multi-target alliance to develop mRNA-based therapies in medical dermatology Read more
AstraZeneca to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with positive Phase II data Read more
Depixus Announces Strategic Collaboration With Daiichi Sankyo To Use MAGNA Technology To Accelerate RNA-Targeted Drug Discovery Read more
Ipsen confirms FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC Read more
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE) and Plans to Expand Vepdegestrant Development Program Read more